Literature DB >> 9548410

Adaptation of cortical NMDA receptors by chronic treatment with specific serotonin reuptake inhibitors.

G Nowak1, B Legutko, P Skolnick, P Popik.   

Abstract

Glycine displaces [3H]CGP-39653 ([3H]D,L-(E)-2-amino-4-propyl-5-phosphono-3-pentenoic acid) binding to the glutamate recognition site with both high and low affinity. We reported previously that chronic treatment with antidepressants reduced the proportion of high to low affinity sites, or, even eliminated the high affinity sites in case of citalopram. Here, we compared the effects of citalopram with another serotonin specific reuptake inhibitor, fluoxetine on this measure. Chronic administration of citalopram or fluoxetine eliminated high affinity glycine-displaceable [3H]CGP-39653 binding to the mouse cortex in 78 and 56% of animals, respectively, indicating that selective serotonin reuptake inhibitors produce qualitatively similar adaptive changes at NMDA receptors, that differ from other antidepressants in this neurochemical measure.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9548410     DOI: 10.1016/s0014-2999(97)01589-6

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  12 in total

Review 1.  New targets for rapid antidepressant action.

Authors:  Rodrigo Machado-Vieira; Ioline D Henter; Carlos A Zarate
Journal:  Prog Neurobiol       Date:  2015-12-23       Impact factor: 11.685

2.  Elevated levels of the NR2C subunit of the NMDA receptor in the locus coeruleus in depression.

Authors:  Beata Karolewicz; Craig A Stockmeier; Gregory A Ordway
Journal:  Neuropsychopharmacology       Date:  2005-08       Impact factor: 7.853

3.  Serotonin inhibition of the NMDA receptor/nitric oxide/cyclic GMP pathway in human neocortex slices: involvement of 5-HT(2C) and 5-HT(1A) receptors.

Authors:  G Maura; M Marcoli; O Pepicelli; C Rosu; C Viola; M Raiteri
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

Review 4.  Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders.

Authors:  Gerard Sanacora; Carlos A Zarate; John H Krystal; Husseini K Manji
Journal:  Nat Rev Drug Discov       Date:  2008-05       Impact factor: 84.694

Review 5.  Advances in the treatment of anxiety: targeting glutamate.

Authors:  Asher B Simon; Jack M Gorman
Journal:  NeuroRx       Date:  2006-01

6.  Reduced isolation-induced aggressiveness in mice following NAALADase inhibition.

Authors:  L A Lumley; C L Robison; B S Slusher; K Wozniak; M Dawood; J L Meyerhoff
Journal:  Psychopharmacology (Berl)       Date:  2003-11-21       Impact factor: 4.530

7.  Adaptive changes in the rat hippocampal glutamatergic neurotransmission are observed during long-term treatment with lorazepam.

Authors:  C Bonavita; A Ferrero; M Cereseto; M Velardez; M Rubio; S Wikinski
Journal:  Psychopharmacology (Berl)       Date:  2003-01-24       Impact factor: 4.530

8.  Modulation of antidepressant-like activity of magnesium by serotonergic system.

Authors:  E Poleszak
Journal:  J Neural Transm (Vienna)       Date:  2007-04-20       Impact factor: 3.575

9.  The absence of P2X7 receptors (P2rx7) on non-haematopoietic cells leads to selective alteration in mood-related behaviour with dysregulated gene expression and stress reactivity in mice.

Authors:  Cecilia Csölle; Rómeó D Andó; Ágnes Kittel; Flóra Gölöncsér; Mária Baranyi; Krisztina Soproni; Dóra Zelena; József Haller; Tamás Németh; Attila Mócsai; Beáta Sperlágh
Journal:  Int J Neuropsychopharmacol       Date:  2012-01-16       Impact factor: 5.176

10.  Neurochemical Changes in the Mouse Hippocampus Underlying the Antidepressant Effect of Genetic Deletion of P2X7 Receptors.

Authors:  Cecilia Csölle; Mária Baranyi; Gabriella Zsilla; Agnes Kittel; Flóra Gölöncsér; Peter Illes; Edit Papp; E Sylvester Vizi; Beáta Sperlágh
Journal:  PLoS One       Date:  2013-06-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.